Generic Name: Ceftazidime pentahydrate
Product Name: Fortum
Used for the treatment of single and mixed infections caused by aerobic organisms with suspected or proven resistance to common antimicrobial agents, though susceptible to ceftazidime. Also used for the treatment of pseudomonal infections in place of aminoglycosides in patients where such first line drugs might be contraindicated.
Severe septicaemia or bacteremia; Respiratory tract infections (e.g. pneumonia); Severe ear, nose, & throat infections; Urinary tract infections; Skin & soft tissue infections; Gastrointestinal & abdominal infections; Bone and joint infections
Ceftazidime is bactericidal, and is active against many bacteria that are resistant to common antibiotics.
Peak serum levels are achieved 1 hour after intramuscular administration, and immediately following completion of intravenous infusion.
Concentrations greater than the minimum inhibitory levels for susceptible organisms are achieved in bone, heart, bile, sputum, aqueous humour and synovial, pleural and peritoneal fluids and ceftazidime readily crosses the placenta. However it has poor penetration of the intact blood brain barrier and cerebrospinal fluid levels are negligible.
Serum half life is 1.8 hours in patients with normal renal function, and up to 20-35 hours in anuric patients. It can be 3-4 times greater in neonates than in adults.
Ceftazidime is not metabolised and is excreted unchanged in the urine.
Standard dosage range: 1-6 g daily, given in divided doses intravenously or intramuscularly, every 8-12 hours.
E.g. 1 g, every 8 hours, OR 2 g, every 12 hours. In very severe infections: 2 g, every 8-12 hours.
Urinary tract infections & less serious infections: 500 mg or 1 g, every 12 hours.
Neonates, infants < 12 months: 25-100 mg/kg/day in 2 divided doses (in neonates, the ceftazidimeâ??s serum half life can be 3-4 times greater than in adults. >12 months: 25-100 mg/kg/day (maximum of 6 g/day), given as 2-3 divided doses.
Impaired renal function.
Adults: Doses should be reduced in patients with impaired renal function (including elderly patients with reduced renal efficacy). In patients with very severe infections who would normally receive 6 g per day, the doses given below may be increased by 50% or the dosing frequency increased.
Creatinine clearance 31-50 mL/min: 1 g, every 12 hours.
Creatinine clearance 16-30 mL/min: 1 g, every 24 hours.
Creatinine clearance 6-15 mL/min: 1 g, every 24 hours.
Creatinine clearance <6 mL/min: 0.5 g, every 48 hours.
Children: Dosage and dosing frequency should be reduced, according to body surface area or lean body mass.
Use in pregnancy and lactation.
Ceftazidime should be only used in pregnant or breastfeeding women if the benefit clearly outweighs the risks.
Common side effects
Ceftazidime is generally well tolerated.
Local reaction at injection site.
Rash, fever, pruritus.
Diarrhoea, nausea, vomiting, abdominal pain
Transient elevations in renal and hepatic biochemistry laboratory values.
Uncommon side effects
Oral and vaginal thrush, vaginitis.
For further information talk to your doctor.